This single-patient success in a devastating pediatric cancer with no alternatives meaningfully de-risks Immatics' PRAME platform. Traders should anticipate increased investor interest ahead of AACR presentation and view this as strong validation for ongoing adult trials (SUPRAME Phase 3 melanoma). Monitor for updates on pediatric trial initiation.
Price Chart
Executive Summary
Immatics announced a deep and durable remission in a pediatric patient with advanced metastatic nephroblastoma treated with its PRAME-directed TCR T-cell therapy, marking a significant clinical proof-of-concept for its platform in pediatric solid tumors. The data will be presented at AACR 2026, reinforcing confidence in PRAME as a high-value target.
Key Facts
- 17-year-old pediatric patient with PRAME-positive advanced nephroblastoma achieved deep remission after treatment with Immatics' PRAME-directed TCR T-cell therapy (IMA203CD8)
- Patient had bulky, rapidly progressing disease with metastases to liver, lung, and brain and no remaining treatment options
- Remission was observed at 3 months and ongoing at 6 months post-infusion, with marked regression on PET/MRI and molecular remission via liquid biopsy
- Safety profile included manageable cytokine release syndrome resolved with standard therapy
- Data to be presented in a late-breaking poster at AACR Annual Meeting 2026
- Immatics is evaluating a potential first-in-pediatrics Phase 1/2 basket study in HLA-A*02:01-positive, PRAME-expressing relapsed/refractory solid tumors
Financial Impact
Positive re-rating potential due to validation of PRAME platform in a new indication with high unmet need; no direct revenue impact yet as clinical-stage
Risk Factors
- Single-patient result; efficacy may not generalize
- Preliminary data subject to verification and potential adverse events with longer follow-up
- No guarantee of regulatory pathway or commercialization in pediatrics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-005872 |
| Document: dp245235_6k.htm | 0000950103-26-005872 |
| Document: 0000950103-26-005872-index-headers.html | 0000950103-26-005872 |
| Document: 0000950103-26-005872-index.html | 0000950103-26-005872 |
| Document: 0000950103-26-005872.txt | 0000950103-26-005872 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.45 $8.50 | ▼ −10.05% | ▼ −10.31% | $7.59 (−19.68%) |
Aug 26, 2026 5w ago | 6-K | $9.36 $8.33 | ▲ +11.00% | ▲ +10.50% | $7.59 (+18.91%) |
Aug 18, 2026 6w ago | 6-K | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Aug 18, 2026 6w ago | Press Release | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Jun 2, 2026 17w ago | 6-K | $10.04 $9.85 | ▼ −1.89% | ▼ −0.33% | $7.59 (−24.40%) |
Jun 1, 2026 17w ago | 6-K | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
Jun 1, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 31, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 30, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 12, 2026 20w ago | 6-K | $11.39 $8.87 | ▲ +22.12% | ▲ +20.40% | $7.59 (+33.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access